A complete application in a minute
Tailored resume and cover letter, ready to send.
The University of Bern invites applications for a PhD project focused on preclinical validation of Aurora kinase A vulnerabilities in FANCA-deficient cancers. You will work in an interdisciplinary team of medical oncologists, pathologists and translational researchers, using patient-derived cancer models and in vivo studies.
The successful candidate has an MSc in Molecular Life Sciences or related field, strong mammalian cell culture skills, and a passion for translational cancer research.
Our laboratory work focuses on molecularly targeted treatment strategies for solid tumours, exploiting DNA repair alterations as therapeutic vulnerabilities to advance precision oncology. In previous work, using a genome-wide CRISPR/Cas9 screen and a high-throughput drug screen, we recently identified Aurora kinase A (AURKA) as a synthetic lethal target in cancers deficient in FANCA, the most frequently altered gene of the Fanconi anaemia DNA repair pathway. The proposed PhD project, will advance the preclinical validation of this newly uncovered vulnerability in clinically relevant patient-derived cancer models and in vivo, identify synergistic targets for combination therapies through functional genomic screening, and characterise the tumour immune microenvironment of Fanconi anaemia pathway-deficient cancers in order to nominate synergistic immunotherapy targets. The position is embedded in an interdisciplinary and multicentric team of medical oncologists, pathologists and basic and translational researchers. The PhD candidate will be enrolled in the Graduate School for Cellular and Biomedical Sciences of the University of Bern.